Jacobio Pharmaceuticals Group Co. Ltd. has received FDA approval of its IND application for JAB-30300, allowing it begin a phase I/IIa trial in the U.S. in advanced solid tumors.
At this week’s EACR-AACR-ICAR meeting in Dublin, Suzhou Kintor Pharmaceuticals Inc. presented preclinical data for the novel MYC- and GSPT1-targeting molecular glue candidate, GT-19630, being developed for the treatment of breast cancer.
Tumors in the stomach and pancreas are known to express claudin 18.2 (CLDN18.2) and the absence of expression in normal tissues makes it an attractive therapeutic target.
T-cell-engaging antibodies (TCEs) are synthetic molecules that redirect T cells to bind to the antigens on the surface of cancer cells to promote tumor elimination. In the case of multiple myeloma (MM), the approvals of anti-CD38 monoclonal antibodies (MAbs), chimeric antigen receptor T-cell therapies (CAR T) targeting B-cell maturation antigen (BCMA) or, more recently, bispecific TCEs represent great advances, but some patients still relapse after treatment.
Researchers from the La Jolla Institute for Immunology (LJI) and collaborators have presented a new platform to identify and validate neoantigens that would otherwise escape traditional routine sampling methods. The project, which they describe in an article published on Feb. 28, 2024, in Science Translational Medicine, started after discussions at the beginning of a cancer vaccine program between teams at UCSD Moores Cancer Center (MCC) and LJI.
China’s National Medical Products Administration (NMPA) cleared 40 novel innovative drugs in 2023, of which nearly half were cancer therapies, marking a significant increase from the 21 new class 1 drugs approved in 2022.
Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an EGFR targeting moiety reported to be useful for the treatment of cancer particularly, non-small-cell lung cancer (NSCLC).
Kyung Hee University has disclosed microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors acting as prostaglandin E2 (PGE2) production inhibitors reported to be useful for the treatment of asthma, atherosclerosis, diabetes, pain, osteoporosis, bursitis, infections and cancer.
The transcription of ribosomal RNA by RNA Polymerase I (Pol I) is an essential step for cells to grow and thus is considered a therapeutic target for cancer treatment.